Sandu Pharmaceuticals Limited Schedules Board Meeting on February 06, 2026 for Q3FY26 Financial Results Approval

1 min read Updated on 24 Jan 2026, 12:14 PM

Reviewed by

Radhika SScanX News Team

Overview

Sandu Pharmaceuticals Limited has scheduled a board meeting for February 06, 2026, at 04:00 PM to approve standalone unaudited financial results for the quarter ended December 31, 2025. The meeting will be held at the company's Mumbai corporate office. In compliance with SEBI insider trading regulations, the company has closed the trading window for directors, officers, and designated employees from January 01, 2026, until 48 hours after the public announcement of quarterly results.

*this image is generated using AI for illustrative purposes only.

Sandu Pharmaceuticals Limited has announced that its Board of Directors will convene on February 06, 2026, to review and approve the company's quarterly financial performance. The meeting represents a key corporate governance milestone as the company prepares to disclose its financial results for the third quarter of fiscal year 2026.

Board Meeting Details

The board meeting is scheduled with specific parameters that reflect the company's commitment to regulatory compliance and transparency.

Parameter:	Details
Meeting Date:	February 06, 2026
Meeting Time:	04:00 PM
Venue:	Corporate Office, Sandu Nagar, D K Sandu Marg, Chembur, Mumbai 400 071
Primary Agenda:	Approval of Standalone Unaudited Financial Results
Reporting Period:	Quarter and period ended December 31, 2025

Financial Results Review

The primary agenda item focuses on the approval of standalone unaudited financial results for the quarter ended December 31, 2025. This quarterly review will provide stakeholders with insights into the company's operational performance during the third quarter of fiscal year 2026. The board will also consider any additional matters that may arise with the chairman's permission.

Regulatory Compliance Measures

In adherence to SEBI regulations regarding insider trading prevention, Sandu Pharmaceuticals has implemented comprehensive compliance measures. The company has established a trading window closure that affects multiple stakeholder categories.

Compliance Aspect:	Details
Trading Window Status:	Closed
Affected Parties:	Directors, Officers, and Designated Employees
Closure Start Date:	January 01, 2026
Closure End:	48 hours after public announcement of financial results
Regulatory Framework:	SEBI Prohibition of Insider Trading regulations

Corporate Communication

The formal communication was issued under reference number SPL/Corp.Sec/2025-26/24 dated January 24, 2026, and addressed to the Bombay Stock Exchange Limited. Company Secretary and Compliance Officer Pratika Mhambray signed the notification, ensuring proper documentation and regulatory adherence. The company operates under scrip code 524703 on the exchange and maintains its corporate office at the specified Mumbai location.

This scheduled board meeting demonstrates Sandu Pharmaceuticals' commitment to maintaining transparent communication with stakeholders and adhering to established corporate governance practices while ensuring compliance with securities market regulations.

Historical Stock Returns for Sandu Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.33%	-15.49%	-13.84%	-32.93%	-37.52%	+0.36%

Sandu Pharmaceuticals

View Company Insights

View All News

Sandu Pharmaceuticals Receives GST Notice for ₹13.00 Lakh Discrepancy

1 min read Updated on 22 Dec 2025, 10:03 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

Overview

Sandu Pharmaceuticals Limited has received a notice from the Maharashtra Department of Goods and Service Tax regarding discrepancies in its GST returns. The notice, issued on December 22, identifies a ₹13.00 lakh discrepancy related to non-reversal of Input Tax Credit in GSTR-3B compared to GSTR-9. The company plans to file a reply and expects a favorable outcome based on internal assessment and legal advice. Sandu Pharmaceuticals anticipates no material impact on its financials or operations.

*this image is generated using AI for illustrative purposes only.

Sandu Pharmaceuticals Limited has received a regulatory notice from the Maharashtra Department of Goods and Service Tax regarding discrepancies identified in its GST returns. The company disclosed this development to BSE Limited on December 22, in compliance with Regulation 30 of SEBI LODR Regulations 2015.

Notice Details and Nature of Discrepancy

The notice was issued by the Government of Maharashtra Department of Goods and Service Tax - Office of The Deputy Commissioner of State Tax. The regulatory action pertains to discrepancies in the return after scrutiny, passed under the Maharashtra Goods & Service Tax Act, 2017, specifically under Rule 99(1) of the Maharashtra Goods & Services Tax Rules, 2017.

Parameter	Details
Issuing Authority	Government of Maharashtra GST Department
Notice Date	December 22
Amount Involved	₹13.00 lakh

Specific Violation Identified

The notice specifically addresses the non-reversal of Input Tax Credit (ITC) in GSTR-3B as compared with GSTR-9. The discrepancy amount identified by the tax authorities stands at ₹13.00 lakh. This type of discrepancy typically arises when there are differences between the monthly/quarterly returns filed (GSTR-3B) and the annual return (GSTR-9).

Company's Response and Assessment

Sandu Pharmaceuticals has indicated that it will be filing a reply to the authorities regarding the notice issued. The company's management has conducted its own assessment of the situation and has also sought legal advice on the matter. Based on this internal evaluation and professional consultation, the management expects a favorable outcome for the notice.

Financial and Operational Impact

The company has assessed that no material impact is envisaged on its financials, operations, or other activities due to this GST notice. The management's confidence in a favorable resolution suggests that the company believes it has adequate documentation and justification to address the discrepancy raised by the tax authorities.

Impact Assessment	Company's Position
Financial Impact	No impact envisaged
Operational Impact	No impact expected
Management Outlook	Expects favorable outcome
Next Steps	Filing reply to authorities

This disclosure demonstrates Sandu Pharmaceuticals' commitment to transparency and regulatory compliance by promptly informing stakeholders about potential regulatory matters that could affect its operations.

Historical Stock Returns for Sandu Pharmaceuticals